Loading...
DTIL logo

Precision BioSciences, Inc.NasdaqCM:DTIL 株式レポート

時価総額 US$186.6m
株価
US$7.23
US$32
77.4% 割安 内在価値ディスカウント
1Y47.9%
7D4.8%
1D
ポートフォリオ価値
​
表示

Precision BioSciences, Inc.

NasdaqCM:DTIL 株式レポート

時価総額：US$186.6m

Precision BioSciences（DTIL）株式概要

プレシジョン・バイオサイエンシズ社は臨床段階にある遺伝子編集会社で、米国で遺伝子の挿入、切除、除去を含む遺伝子編集のための生体内遺伝子編集療法を開発している。 詳細

DTIL ファンダメンタル分析
スノーフレーク・スコア
評価5/6
将来の成長2/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

当社が推定した公正価値より90.4%で取引されている

収益は年間22.74%増加すると予測されています

同業他社や業界と比較して、良好な取引価格

リスク分析

今後3年間の収益は年平均3.9%減少すると予測されている。

過去1年間で株主の希薄化は大幅に進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

US市場と比較した過去 3 か月間の株価の変動


DTIL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Precision BioSciences, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Precision BioSciences
過去の株価
現在の株価US$7.23
52週高値US$8.82
52週安値US$3.53
ベータ1.31
1ヶ月の変化2.70%
3ヶ月変化76.34%
1年変化47.85%
3年間の変化-71.31%
5年間の変化-97.77%
IPOからの変化-98.62%

最新ニュース

分析記事 • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...

Recent updates

分析記事 • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
分析記事 • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
分析記事 • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
分析記事 • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1
Seeking Alpha • Aug 16

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022. Precision has established several partners for use of its ARCUS in vivo gene editing platform; these partners are Eli Lilly, Novartis and iEcure. Company has enough cash to fund its operations until the end of 2024, giving plenty of cash runway for the foreseeable future. Precision BioSciences, Inc. (DTIL) is a great speculative biotech play to look into. That's because it is advancing an allogeneic CAR-T pipeline, along with an in vivo gene editing pipeline. Speaking of its CAR-T treatments, the main one in the pipeline would be PBCAR0191, which is being explored in a phase 1/2 study in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. In the most recent interim update, it noted that relapsed patients given this CAR T were able to achieve a 100% response rate. Why I believe it may have some potential upside is because Precision expects to release updated results from this very same study before the end of 2022. In addition, it has a pretty solid pipeline when it comes to in vivo gene editing as well. It has several wholly owned treatments and then it has many others which have already been partnered with a few pharmaceutical companies. With proof of concept established using PBCAR0191 for the treatment of patients with relapsed/refractory NHL B-cell ALL, plus an update on data from the phase 1/2 study expected before the end of 2022, these are the reasons why I believe that Precision Biosciences is a great speculative biotech play to look into. PBCAR0191 For Treatment Of Patients With Non-Hodgkin's Lymphoma And B-Cell Acute Lymphoblastic Leukemia The main program to go over involves the use of PBCAR0191, which is being developed for the treatment of patients with non-Hodgkin's lymphoma ((NHL)) and B-Cell Acute Lymphoblastic Leukemia (B-ALL). Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. This is not the only difference between Hodgkin's and Non-Hodgkin's lymphoma. Hodgkin's Lymphoma is a rare type of lymphoma and only about 8,500 cases diagnosed in 2016. This compares to Non-Hodgkin's Lymphoma which had 72,500 cases were diagnosed in 2016 and is the seventh most diagnosed type of cancer. In addition, there is a difference in 5-year survival rates, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a very large market opportunity for Precision Biosciences. The use of PBCAR0191 is being explored in an ongoing phase 1/2a study, which demonstrated that it could achieve high response rates in patients who relapsed after CAR T. This trial is an open-label, dose-escalation and dose expansion study to evaluate safety and efficacy of PBCAR0191 in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. Speaking of dose level and dose expansions, it is expected that Precision Biosciences could reach up to 6 dose levels total. What I will show below is that the biotech was able to achieve high response rates in a very sick patient population. How sick? Well consider that these are CAR T relapsed patients who received on average 5 prior lines of treatments. That means they gone through and failed multiple types of treatments, along with other CAR T, before entering this particular study. The positive results released as an update in June of 2022 layout the most recent dose levels which were used for this study. These dose levels used for PBCAR0191 were dose level 3 (DL3) with enhanced lymphodepletion (treatment to kill existing T-cells to make room for new ones) in 6 patients and then dose level 4 (DL4b) with reduced/decreasing lymphodepletion in another 6 patients (This dose level is referred to as the "New Cohort" or latest cohort as of January 2022). As of the May 31, 2022 cutoff date, the breakdown for each dose level cohort noted directly above is as follows: It noted that 11 out of 11 (100%) of patients achieved an objective response rate (ORR) It was said that 8 out of 11 patients achieved a complete response rate 6 patients from the pool of 11 patients remain with an ongoing response for 18 months + The data for which I highlighted above deals with both dose level cohorts (DL3 and DL4b). However, what I find intriguing is that the dose level 4b cohort (new cohort), had shown to be superior over dose level 3. This was even achieved with a reduction of lymphodepletion as well, which is always good for safety in the end. This is good news for Precision Biosciences, because it is targeting a huge unmet need. These are patients with aggressive lymphomas who fail on autologous CAR Ts and other therapies. There is no approved standard of care ((SOC)) for these patients and their progression-free survival for the time being is a mere 2 months. As far as a catalyst goes, there will be an update on the use of PBCAR0191 for the treatment of patients with relapsed/refractory NHL towards the end of 2022. In addition, to updates on the other CAR Ts in the pipeline which are PBCAR19B and PBCAR269A, which are being developed for the treatment of patients with NHL and Multiple Myeloma ((MM)) respectively. It will likely be an update on data and maybe even plans for the next study. The biotech intends to meet with the FDA to discuss the data observed and then see what it needs to do next to advance it. The hope is that it can continue to reduce the amount of lymphodepletion patients need with treating their aggressive lymphomas. This could both improve safety and efficacy of PBCAR0191. Two Massive Partnerships Worth Billions Of Dollars In Potential Milestone Payments The thing is that Precision Biosciences uses its ARCUS gene editing technology for its pipeline. It remains to be seen how well it does when it is actually utilized in humans, however, it has already attracted the attention of several pharmaceutical companies. One of the most recent partnerships for licensing the ARCUS in vivo gene editing technology involves Novartis (NVS). Novartis wanted to enter this deal to get its hands on the ARCUS gene editing technology. Precision Biosciences received an upfront payment of $75 million. That's a good start to help fund its operations, but the real deal happens if it can meet all of its milestones and earn up to $1.4 billion in cash. Of course, should any product reach the market it will obtain the usual tiered royalties on sales. Its main job will be to develop a single ARCUS nuclease that is safe and efficient for In Vivo gene insertion. The goal is to attempt to develop cures for large markets like sickle cell disease and beta thalassemia. The thalassemia market is expected to reach $3.53 billion in 2022. On the other hand, the other market opportunity is much larger. It is expected that the sickle-cell disease market will reach $5.5 billion in 2023. These are the initial indications for which Novartis wants to happen. I believe that an in vivo ARCUS nuclease will be developed. The test is whether or not such a product is efficient when it delivered to humans in a phase 1 study. These indications are just the start of what is possible. That's because the partnership could eventually expand to other hemoglobinopathies that exist out there.

株主還元

DTILUS BiotechsUS 市場
7D4.8%3.1%1.2%
1Y47.9%34.6%28.7%

業界別リターン: DTIL過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: DTIL過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。

価格変動

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement11.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: DTILの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: DTILの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
200666Michael Amorosoprecisionbiosciences.com

プレシジョン・バイオサイエンシズ社は臨床段階の遺伝子編集企業で、米国で遺伝子の挿入、切除、除去を含む遺伝子編集のためのin vivo遺伝子編集療法を開発している。同社はDNAゲノム挿入、除去、修復のためのゲノム編集プラットフォームARCUSを提供している。また、慢性B型肝炎ウイルス（HBV）の治療薬として、共有結合で閉じた環状DNAを直接切断・編集して除去し、統合型HBV DNAを不活性化してB型肝炎表面抗原の長期的な減少を目指すPBGENE-HBV、デュシェンヌ型筋ジストロフィーの治療薬としてPBGENE-DMD（切除）を提供している。さらに、m.3243に関連するミトコンドリア病の治療薬PBGENE-3243、オルニチン・トランスカルバミラーゼ欠損症の治療薬iECURE-OTC（Insertion）を開発している。また、TG Cell Therapy, Inc.とは、自己免疫疾患などを適応症とするazercabtagene zapreleucel、ARCUSを介した標的遺伝子挿入であるiECURE, Inc.の開発、製造、商品化に関する提携契約を結んでいる。プレシジョン・バイオサイエンシズ社は2006年に設立され、ノースカロライナ州ダーラムに本社を置いている。

Precision BioSciences, Inc. 基礎のまとめ

Precision BioSciences の収益と売上を時価総額と比較するとどうか。
DTIL 基礎統計学
時価総額US$186.55m
収益（TTM）-US$44.48m
売上高(TTM)US$45.07m
4.1x
P/Sレシオ
-4.2x
PER（株価収益率

DTIL は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
DTIL 損益計算書（TTM）
収益US$45.07m
売上原価US$0
売上総利益US$45.07m
その他の費用US$89.56m
収益-US$44.48m

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）-1.72
グロス・マージン100.00%
純利益率-98.70%
有利子負債／自己資本比率29.5%

DTIL の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/26 11:16
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Precision BioSciences, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.